Literature DB >> 14698803

In vitro senescence of immune cells.

Rita B Effros1, Mirabelle Dagarag, Hector F Valenzuela.   

Abstract

Immune cells are eminently suitable model systems in which to address the possible role of replicative senescence during in vivo aging. Since there are more than 10(8) unique antigen specificities present within the total T lymphocyte population of each individual, the immune response to any single antigen requires massive clonal expansion of the small proportion of T cells whose receptors recognize that antigen. The Hayflick Limit may, therefore, constitute a barrier to effective immune function, at least for those T cells that encounter their specific antigen more than once over the life course. Application of the fibroblast replicative senescence model to the so-called cytotoxic or CD8 T cell, the class of T cells that controls viral infection and cancer, has revealed certain features in common with other cell types as well as several characteristics that are unique to T cells. One senescence-associated change that is T cell-specific is the complete loss of expression of the activation signaling surface molecule, CD28, an alteration that enabled the documentation of high proportions of senescent T cells in vivo. The T cell model has also provided the unique opportunity to analyze telomere dynamics in a cell type that has the ability to upregulate telomerase yet nevertheless undergoes senescence. The intimate involvement of the immune system in the control of pathogens and cancer as well as in modulation of bone homeostasis suggests that more extensive analysis of the full range of characteristics of senescent T cells may help elucidate a broad spectrum of age-associated physiological changes.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14698803     DOI: 10.1016/j.exger.2003.09.004

Source DB:  PubMed          Journal:  Exp Gerontol        ISSN: 0531-5565            Impact factor:   4.032


  12 in total

1.  Assessment of telomere length, phenotype, and DNA content.

Authors:  Ingrid Schmid; Beth D Jamieson
Journal:  Curr Protoc Cytom       Date:  2004-09

2.  Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.

Authors:  Jianping Huang; Hung T Khong; Mark E Dudley; Mona El-Gamil; Yong F Li; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2005 May-Jun       Impact factor: 4.456

Review 3.  The silent war of CMV in aging and HIV infection.

Authors:  Rita B Effros
Journal:  Mech Ageing Dev       Date:  2015-09-25       Impact factor: 5.432

Review 4.  Two-Step Senescence-Focused Cancer Therapies.

Authors:  Cynthia J Sieben; Ines Sturmlechner; Bart van de Sluis; Jan M van Deursen
Journal:  Trends Cell Biol       Date:  2018-05-17       Impact factor: 20.808

5.  IFN-α inhibits telomerase in human CD8⁺ T cells by both hTERT downregulation and induction of p38 MAPK signaling.

Authors:  Alessio Lanna; Elias Coutavas; Lauretta Levati; Judith Seidel; Malcolm H A Rustin; Sian M Henson; Arne N Akbar; Ornella Franzese
Journal:  J Immunol       Date:  2013-08-30       Impact factor: 5.422

6.  Assessment of Telomere Length, Phenotype, and DNA Content.

Authors:  Theodoros Kelesidis; Ingrid Schmid
Journal:  Curr Protoc Cytom       Date:  2017-01-05

7.  Roy Walford and the immunologic theory of aging.

Authors:  Rita B Effros
Journal:  Immun Ageing       Date:  2005-04-25       Impact factor: 6.400

Review 8.  Cellular senescence impact on immune cell fate and function.

Authors:  Rita Vicente; Anne-Laure Mausset-Bonnefont; Christian Jorgensen; Pascale Louis-Plence; Jean-Marc Brondello
Journal:  Aging Cell       Date:  2016-02-22       Impact factor: 9.304

Review 9.  Immunosenescence, aging, and systemic lupus erythematous.

Authors:  Gladis Montoya-Ortiz
Journal:  Autoimmune Dis       Date:  2013-10-24

10.  Prostaglandin E2 promotes features of replicative senescence in chronically activated human CD8+ T cells.

Authors:  Jennifer P Chou; Christina M Ramirez; Danielle M Ryba; Megha P Koduri; Rita B Effros
Journal:  PLoS One       Date:  2014-06-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.